The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans

Journal of Clinical Investigation

Volumn 97, Issue 3, 1996, Pages 642-648

  Roden, Michael ^a   Perseghin, Gianluca ^a   Petersen, Kitt Falk ^a   Hwang, Jong Hee ^a   Cline, Gary W ^a   Gerow, Karynn ^a   Rothman, Douglas L ^a   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

13C NMR spectroscopy; acetaminophen; glucoacogenesis; somatostatin

Indexed keywords

GLUCAGON; GLYCOGEN; INSULIN;

ADULT; ARTICLE; GLUCAGON RELEASE; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIVER METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030023775     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118460     Document Type: Article

References (48)

1. Moore M.C., A.D. Cherrington, G. Cline, M.J. Pagliassotti, E.M Jones, D W. Neal, C Badet, and G I. Shulman 1991 Sources of carbon for hepatic glycogen synthesis in the conscious dog J. Clin Invest 88:578-587.
2. 13C nuclear magnetic resonance spectroscopy study. J. Clin Invest. 95:783-787
3. Unger, R H., and L. Orci 1975. The essential role of glucagon in the pathogenesis of diabetes mellitus Lancet. i.14-16
4. Exton, J.H., and C R. Park 1967. Control of gluconeogenesis in liver. J. Biol. Chem 242:2622-2636.
5. Hems, D A., P.O. Whitton, and E A Taylor 1972. Glycogen synthesis in the perfused liver of the starved rat. Biochem. J. 129:529-538.
6. Katz, J., S. Golden, and P.A Wals. 1976. Stimulation of hepatic glycogen synthesis by amino acids Proc Natl Acad. Sci. USA. 73:3433-3437.
7. Hers, H.G. 1976. The control of glycogen metabolism in the liver. Annu. Rev. Biochem. 45:167-189.
8. Shulman, G.I., and B.R. Landau. 1992. Pathways of glycogen repletion. Physiol. Rev 72:1019-1035.
9. 13C NMR. Science (Wash. DC). 254:573-576.
10. Nilsson, L.H., and E. Hultman. 1974. Liver and muscle glycogen in man after glucose and fructose infusion. Scand J. Clin. Lab. Invest. 33:5-10.
11. Magnusson, I., D.L. Rothman, B. Jucker, G.W. Cline, R.G. Shulman, and G.I Shulman. 1994. Liver glycogen turnover in fed and fasted humans. Am. J. Physiol. 266:E796-E803.
12. Wajngot, A., V. Chandramouli, W.C. Schumann, K. Kumaran, S. Efendic, and B.R. Landau. 1989. Testing of the assumptions made in estimating the extent of futile cycling Am J. Physiol. 256:E668-E675.
13. 13C-nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus. J. Clin. Invest. 94:2369-2376.
14. DeFronzo, R.A., J.D. Tobin, and R. Andres. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237:E214-E223.
15. 13C nuclear magnetic resonance spectroscopy N Engl. J. Med. 322:223-228.
16. Hohorst, H.J. 1965. L-(+)-lactate determination with lactic dehydrogenase. In Methods of Enzymatic Analysis. H.U. Bergmeyer, editor. Verlag Chemie, Basel. 266-270.
17. Miles, J., R. Glasscock, J. Aikens, J. Gerich, and M. Haymond. 1983. A microfluorimetric method for the determination of free fatty acids in plasma. J. Lipid Res. 24:96-99
18. Wolfe, R.R. 1992. Radioactive and Stable Isotope Tracers in Biomedicine Wiley-Liss, New York.
19. Shulman, G.I., G. Cline, W.C. Schumann, V. Chandramouli, K. Kumaran, and B.R. Landau. 1990. Quantitative comparison of pathways of hepatic glycogen repletion m fed and fasted humans. Am J. Physiol. 259:E335-E341.
20. Blackard, W.G. and N.C. Nelson. 1970. Portal and peripheral vein immunoreactive insulin concentrations before and after glucose infusion. Diabetes. 19:302-306.
21. Horwitz, D.L., J.I. Starr, M.E. Mako, W.G. Blackard, and A.H. Rubenstein. 1975. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J. Clin Invest. 55:1278-1283.
22. DeFronzo, R.A , E. Ferrannini, R. Hendler, P. Felig, and J. Wahren. 1983. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 32:35-45.
23. Kolterman, O.G., J. Insel, M. Saekow, and J.M. Olefsky 1980 Mechanisms of insulin resistance in human obesity Evidence for receptor and post-receptor defects. J. Clin. Invest. 65:1272-1284.
24. Rizza, R.A., L.J. Mandarino, and J.E Gerich. 1981. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am. J. Physiol. 240:E630-E639.
25. Shulman, G.I., J.E. Liljenquist, P.E. Williams, and W.W. Lacy. 1978. Glucose disposal during insulinopenia in somatostatin-treated dogs. The roles of glucose and glucagon. J Clin. Invest. 62:487-491.
26. Liljenquist, J.E., Z.T. Bloomgarden, A.D. Cherrington, J.M. Perry, and D. Rabin. 1979. Possible mechanism by which somatostatin-induced glucagon suppression improves glucose tolerance during insulinopaenia in man. Diabetologia 17:139-143.
27. Holste, L., C. Connoly, and A. Cherrington. 1993. Glucagon can alter net hepatic glucose uptake and glycogen metabolism during intraportal glucose delivery in the conscious dog. Diabetes 42:243A.
28. Jaspan, J.B., J. Ruddick, and E. Rayfield. 1983. Transhepatic glucagon gradients in man: evidence for glucagon extraction by human liver. J. Clin. Endocrinol. & Metab. 58:287-292.
29. Liljenquist, J.E , G.L. Mueller, A.D. Cherrington, J.M. Perry, and D. Rabinowitz. 1979. Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man. J. Clin. Endocrinol. & Metab. 48: 171-175.
30. Saccá, L., M. Cicala, B. Trimarco, B. Ungaro, and C. Vigorito. 1982. Differential effects of insulin on splanchnic and peripheral glucose disposal after an intravenous glucose load in man. J Clin Invest. 70:117-126.
31. Chiasson, J.-L., J.E. Liljenquist, B.C. Sinclair-Smith, and W.W. Lacy. 1975. Gluconeogenesis from alanine in normal postabsorptive man: intrahepatic stimulatory effect of glucagon. Diabetes. 24:574-584.
32. Stevenson, R.W., K.E. Steiner, M.A. Davis, G.K. Hendrick, P.E. Williams, W.W. Lacy, L. Brown, P. Donahue, D B. Lacy, and A.D. Cherrington. 1987. Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo. Diabetes. 36:382-389
33. Granner, D.K., and R.M. O'Brien. 1992. Molecular physiology and genetics of NIDDM: importance of metabolic staging. Diabetes Care 15:369-395
34. Groen, A.K., R.C. Vervoorn, R. Van der Meer, and J.M. Tager. 1983 Control of gluconeogenesis in rat liver cells. I. Kinetics of the individual enzymes and the effect of glucagon. J. Biol. Chem. 258:14346-14353.
35. Raskin, P., and R.H. Unger. 1978. Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetes Diabetes. 27:411-419.
36. Gerich, J.E., E. Tsalikian, M. Lorenzi, V. Schneider, N.V. Bohannon, G. Gustafson, and J.H. Karam. 1975. Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin. J. Clin Endocrinol. & Metab. 41, 1178-1180.
37. Dinneen, S., A. Alzaid, J. Miles, and R. Rizza. 1993. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin. Invest. 92:2283-2290.
38. Gerich, J.E., M Lorenzi, J.H. Karam, V. Schneider, and P.H. Forsham 1975. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. J. Am. Med. Assoc. 234:159-165.
39. Gerich, J., M Lorenzi, V. Schneider, J.H. Karam, J. Rivier, R Guillemin, and P H. Forsham. 1974. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. N. Engl. J. Med. 291:544-547.
40. Christensen, S.E , A.P. Hansen, J. Weeke, and K. Lundbaek. 1977. 24-hour studies of the effects of somatostatin on the levels of plasma growth hormone, glucagon, and glucose in normal subjects and juvenile diabetics. Diabetes 27:300-306.
41. Spinas, G.A., A. Bock, and U. Keller. 1985. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care. 8:429-435.
42. Plewe, G., G. Nölken, U. Krause, E. DelPozo, and J. Beyer 1986. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scand. J. Gastroenterol. 21(Suppl. 119):166-169.
43. Grossman, L.D., S.L. Shumak, S.R. George, W. Singer, and B. Zinman 1989. The effects of SMS 201-995 (Sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus J Clin Endocrinol & Metab. 68:63-67.
44. Osei, K., T.M. O'Dorsio, W.B. Malarkey, E.L. Craig, and S. Cataland 1989. Metabolic effects of long-acting somatostatin analogue (Sandostatin) in type I diabetic patients on conventional therapy. Diabetes. 38:704-709.
45. Dimitriades, G., P. Tessari, and J. Gerich. 1983. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus. Metab. Clin. Exp. 32:987-992.
46. Serrano Rios, M., I. Navascues, J. Saban, A. Ordoñez, F. Sevilla, and E. Del Pozo. 1986. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J. Clin Endocrinol. & Metab. 63:1071-1074.
47. Wahren, J., and P. Felig. 1976. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet ii:1213-1216
48. Dinneen, S., A. Alzaid, D. Turk, and R. Rizza. 1995. Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM. Diabetologia 38:337-343.